期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 121, 期 5, 页码 1673-1680出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI45449
关键词
-
资金
- NIH [HL093294, HL102547, CA18029, AI26672]
- Roche Laboratories
- Vical Inc.
- Viropharma Inc.
- Chimerix Inc.
Human cytomegalovirus (CMV), one of the eight herpesviruses that commonly infect humans, is best known for its propensity to cause disease in immunocompromised patients, especially transplant recipients, patients with advanced AIDS, and congenitally infected newborns. Advances in molecular virology coupled with improvements in diagnostic methods and treatment options have vastly improved our understanding of and ability to manage CMV, but many uncertainties remain, including the mechanisms of persistence and pathogenesis and its hypothesized roles in a variety of human illnesses. Here we review recent advances that are reshaping our view and approach to this fascinating virus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据